This appears largely due to the ability of GIPR agonism to suppress the nausea caused by GLP1R agonism
Fiber supplements are generally safe and complementary to the postbiotic mechanism in resM
ADA 2025 Guideline Alignment: Cardiometabolic Prioritization The ADA 2025 framework reflects CVOT insights: Prioritize GLP-1 RAs with proven CV benefit and SGLT2 inhibitors for high-risk ASCVD , heart failure, and CKD For CKD , SGLT2 inhibitors remain first-line
Tirzepatide became the first dual GLP/GLP-1 receptor agonist to gain FDA approval for treating T2DM in 2022 and obesity in 2023 [ Table 2 ]
Results Variability Disclaimer : Individual results from any dietary supplement vary significantly based on diet, activity level, metabolic baseline, consistency of use, and other individual factors
The result: reduced risk for depression and improved mental health